Creative Touch Permanent Makeup and Aesthetics

Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is the regulatory counterpart to KLK5 – the protein that determines whether the epidermal protease cascade runs at the controlled rate required for healthy desquamation, or at the dysregulated rate that produces inflammatory skin disease. It is encoded by SPINK5, processed intracellularly by furin into a family of biologically active inhibitory fragments, secreted into the stratum corneum intercellular spaces, and there held in pH-dependent complex with KLK5 – inhibiting the protease tightly in the deeper, structurally intact corneal layers and releasing it precisely in the superficial layers where desquamation is appropriate. The pH gradient of the stratum corneum is therefore not merely an antimicrobial feature of healthy skin. It is the mechanism by which LEKTI releases KLK5 in exactly the right place.

When SPINK5 is mutated and LEKTI is absent – Netherton syndrome – KLK5 runs unchecked, destroys corneodesmosomes at every corneal depth, degrades filaggrin, overprocesses hCAP18 to excess LL-37, and obliterates barrier integrity from birth. When SPINK5 carries common polymorphisms rather than null mutations – as it does in a proportion of the atopic dermatitis population – LEKTI is reduced rather than absent, KLK5 is partially dysregulated rather than fully uncontrolled, and the result is an amplified contribution to the barrier deficit. And when the acid mantle is disrupted by alkaline cleansers or hard water in rosacea or AD – LEKTI’s pH-dependent grip on KLK5 loosens without any genetic change at all. The same biology. Different magnitudes. The same direction of harm. ^[4]

LEKTI is not a protein that appears in most discussions of skin biology, even in clinical or scientific contexts. It operates at a regulatory level – controlling an enzyme rather than performing a visible function itself – and the clinical consequences of its absence, while catastrophic, are associated with a rare condition that most practitioners will never encounter directly. But LEKTI’s biology explains a remarkable amount of what goes wrong in the skin diseases that practitioners do encounter constantly: rosacea, atopic dermatitis, impaired desquamation in aged skin, and the post-procedure barrier vulnerability that makes some clients significantly harder to treat than others. Understanding LEKTI is understanding why the acid mantle matters at a molecular level, and why its disruption is not a cosmetic inconvenience but a failure of a precision regulatory mechanism.

Structure: a 15-domain inhibitory architecture

LEKTI is encoded by SPINK5 and belongs to the Kazal family of serine protease inhibitors – a family characterised by the inhibitory Kazal domain, a roughly 50-60 amino acid structure stabilised by three disulphide bridges that forms a hairpin loop presenting directly into the active site of target serine proteases. What makes LEKTI unusual within this family is scale: where most Kazal inhibitors have between three and seven tandem domains, LEKTI has fifteen – the largest Kazal-type inhibitor identified in humans, encoded as a 1,064 amino acid precursor of approximately 145 kDa. ^[3]

Three isoforms are generated from the SPINK5 gene through alternative pre-mRNA processing: the full-length 15-domain form (145 kDa, most abundant), a shorter 13-domain form (125 kDa, from an alternative polyadenylation signal), and a longer 148 kDa form carrying a 30-amino acid insertion between domains 13 and 14 (from cryptic splice junction activation). All three isoforms are expressed in normal human keratinocytes and undergo similar intracellular processing. ^[4]

LEKTI precursors are synthesised in the granular layer keratinocytes, processed intracellularly by furin – a subtilisin-like proprotein convertase cleaving at dibasic residue sites distributed throughout the 14 linker regions between domains – and secreted not as intact precursors but as a family of smaller inhibitory fragments into the stratum corneum intercellular space. The biologically active LEKTI forms present in the epidermis are these fragments, not the precursor. Furin-deficient cells transfected with SPINK5 secrete unprocessed precursor that is functionally inert – establishing furin cleavage as essential to LEKTI activation. ^[4]

The inhibitory fragment family that matters most for KLK regulation consists of: D1 (inactive – cannot inhibit any tested serine protease despite structural integrity), D5, D6, D8–D11, and D9–D15. Of these, D8–D11 is the most potent and most relevant – the fragment that shows the strongest KLK5 inhibition with a Ki of 3.7 nM, a value reflecting extremely tight, rapidly forming binding. The kinetics analysis by surface plasmon resonance characterised this as rapid association and near-irreversible binding at physiological pH – the complex that holds KLK5 in check throughout the deeper stratum corneum. ^[4]

The domain-specific inhibitory profile is not uniform:

D8–D11 is the regulatory heavyweight. Its Ki for KLK5 at 3.7 nM means it binds KLK5 with approximately 10-fold higher affinity than D5, 22-fold higher than D6, and 32-fold higher than D9-D15. The epidermis produces the full fragment repertoire – but D8–D11 is doing the most critical regulatory work. ^[4]

The pH-dependent release mechanism

The most elegant feature of the LEKTI/KLK5 system is not the inhibition itself but the conditional nature of it. LEKTI does not simply bind KLK5 and inactivate it permanently throughout the stratum corneum. It holds KLK5 in pH-dependent complex – the interaction strength varying as a direct function of the pH environment in which the complex is sitting.

Surface plasmon resonance analysis of the D8–D11/KLK5 interaction confirmed that the binding affinity is substantially reduced at the lower pH values characteristic of the superficial stratum corneum. The mechanism: as corneocytes mature toward the skin surface, the local pH in the intercellular spaces transitions from approximately pH 7.0 at the stratum granulosum/corneum junction toward pH 4.5–5.5 at the skin surface – driven by the progressive secretion of fatty acids from lamellar bodies and the acidification of the extracellular milieu. At the more alkaline pH of the deeper corneum, LEKTI holds KLK5 tightly: the complex is stable, KLK5 activity is suppressed, and corneodesmosomal adhesion proteins remain intact. As pH decreases toward the surface, the LEKTI–KLK5 interaction weakens and KLK5 is released as active enzyme – permitted to cleave desmoglein-1, corneodesmosin, and desmocollin-1, initiating corneocyte detachment precisely where it should occur. ^[4]

This is the stratum corneum pH gradient’s most important biological function – more important, arguably, than its antimicrobial effects or its influence on lipid processing enzymes. It is the spatial gating mechanism for the entire desquamation process. The skin surface sheds at the correct rate, in the correct location, without undermining the structural integrity of the barrier beneath – because LEKTI’s pH-dependent release of KLK5 is precisely calibrated to the depth at which corneocytes are ready for detachment.

Any condition or intervention that raises skin surface pH – alkaline surfactants, hard water mineral deposition, barrier dysfunction, sebum decline – shifts the pH gradient upward throughout the stratum corneum, moving the LEKTI release point deeper into the barrier where corneodesmosomes should remain intact. The result is KLK5 activity in layers it should not reach. Not dramatically, not catastrophically – but measurably, continuously, and with cumulative consequences for desquamation rate, filaggrin integrity, and LL-37 production. ^[7]

Netherton syndrome: LEKTI absence – the genetic experiment

Netherton syndrome (NS) is caused by biallelic loss-of-function mutations in SPINK5 – the complete or near-complete absence of functional LEKTI. It is autosomal recessive, estimated prevalence approximately 1 in 200,000, and represents the most severe clinical demonstration of what KLK5 does when its primary inhibitor is absent. ^[8]

The mutation spectrum is broad: nonsense mutations (22%), frameshift insertions/deletions (44%), and splice-site defects (33%) – all producing premature termination codons and absent or severely reduced LEKTI protein. Variable levels of nonsense-mediated mRNA decay mean that some mutations produce more residual LEKTI than others – which partly explains the phenotypic spectrum from severe congenital presentation to milder adolescent-onset disease. ^[1]

Genotype-phenotype correlation. Two 2025 studies provided the most detailed genotype-phenotype mapping yet available:

A Frontiers in Genetics 2025 analysis of 162 NS patients (324 alleles) identified domainR-1 and domainR-5 as the primary mutation hotspots – the two SPINK5 domain regions where variants cluster most densely. Critically, variants in the 5′ half of the SPINK5 gene (upstream, affecting N-terminal domains) were significantly associated with more severe phenotypes, including failure to thrive and infantile death. Variants in the 3′ half (downstream, affecting C-terminal domains) were associated with milder presentations – consistent with the observation that the N-terminal LEKTI fragments are those most expressed in early differentiation stages and most critical to initial corneal barrier formation. ^[10]

A Journal of Allergy and Clinical Immunology: In Practice 2026 study of six SPINK5 variants – including two novel ones – confirmed that FR1-related variants produce severe phenotypes whilst FR5-related variants produce milder disease, and established that immune skewing differs between genotypes: FR1-variant patients show predominantly Th2 skewing, while FR5-variant patients show Th17-dominant responses. This genotype-dependent cytokine skewing has direct implications for biologic therapy selection – dupilumab (anti- IL-4/ IL-13) would be the logical agent for Th2-dominant NS; IL-17 targeting would be more appropriate for Th17-dominant presentations. Early reports of inconsistent paediatric outcomes with dupilumab in NS may partly reflect this genotype-driven immunological heterogeneity. ^[11]

The phenotypic cascade from absent LEKTI:

The PLoS Genetics 2015 double-knockout study – generating SPINK5/KLK5 double-null mice – established the precise causal chain. In SPINK5-null mice, KLK5 genetic deletion rescued neonatal lethality, restored epidermal architecture, normalised filaggrin expression, and reversed the barrier defect – proving that KLK5 hyperactivity, not LEKTI absence itself, is the proximate cause of the NS phenotype. ^[5]

The cascade without KLK5 restraint:

1. Corneodesmosomal degradation at all corneal depths – desmoglein-1, corneodesmosin, and desmocollin-1 cleaved throughout the full thickness of the stratum corneum simultaneously, producing the constant, premature corneocyte shedding that manifests as ichthyosis linearis circumflexa (the pathognomonic double-edged migratory scaly plaques) ^[12]

2. Filaggrin loss – both direct KLK5 cleavage of filaggrin monomers and disrupted profilaggrin processing producing near-absent filaggrin in the granular layer; filaggrin immunostaining almost completely absent in SPINK5-null skin versus full restoration in the double-null ^[5]

3. Excess LL-37 generation – uncontrolled hCAP18 cleavage producing chronic LL-37 overproduction with full mast cell degranulation, vascular activation, and neutrophil recruitment consequences ^[7]

4. Allergen penetration and hyperallergic phenotype – destroyed barrier with no intact corneodesmosomal architecture enabling massive allergen contact sensitisation; elevated total IgE, eosinophilia, and multi-allergen sensitisation are universal NS features ^[6]

5. IL-17 and IL-22 elevation – LEKTI deficiency dysregulates cytokine production directly; SPINK5-null skin shows elevated IL-17 and IL-22 mRNA, with concurrent S100A7/A8/A9 alarm-in upregulation and mast cell and neutrophil infiltration; the inflammatory environment self-sustains independently of allergen exposure ^[11]

SPINK5 polymorphisms in atopic dermatitis

Beyond the null mutations of NS, common SPINK5 polymorphisms have been identified as genetic risk factors for atopic dermatitis in the non-NS population. These are not loss-of-function mutations – they produce reduced or subtly dysfunctional LEKTI rather than its complete absence. The phenotype is accordingly not NS but an amplified contribution to the KLK5 dysregulation and barrier deficit characteristic of AD.

The E420K polymorphism (rs2303067) and several other SPINK5 variants have been associated with elevated atopic disease risk in multiple populations. The proposed mechanism is reduced LEKTI secretion efficiency or reduced inhibitory potency, producing a partial KLK5 dysregulation that accelerates corneodesmosomal protein degradation, contributes to filaggrin deficiency through active cleavage of the existing protein, and enhances the alkaline-pH KLK5 disinhibition effect that the AD skin surface pH already promotes. ^[3]

The clinical implication is not that SPINK5 genotyping is required in AD management – it is not. But it provides mechanistic coherence for why some AD patients have significantly more pronounced barrier fragility than their inflammatory severity alone predicts. A patient with both FLG null mutations and SPINK5 risk variants is experiencing filaggrin deficit from two non-redundant routes simultaneously: reduced FLG expression (genetic) and active KLK5-mediated filaggrin degradation (enzymatic). Managing the KLK5/LEKTI/pH axis in these clients through acid mantle support is addressing both routes in parallel. ^[7]

LEKTI in rosacea

In rosacea, LEKTI is not absent and SPINK5 is not mutated. But the acid mantle disruption characteristic of rosacea-affected skin – elevated surface pH from barrier dysfunction, alkaline cleansers, and the inflammatory process itself – reduces the effective inhibitory capacity of whatever LEKTI is present by shifting the entire LEKTI/KLK5 complex toward the lower-affinity, higher-pH release condition. KLK5 activity exceeds what pH-weakened LEKTI can contain, generating the LL-37 excess and aberrant processing fragments described in the KLK5 entity. ^[9]

Rosacea skin also shows evidence of elevated serine protease inhibitor consumption – LEKTI fragments are depleted in heavily affected areas relative to perilesional skin, consistent with LEKTI being consumed faster than it is produced in the context of ongoing KLK5 hyperactivity. The regulatory deficit is both functional (pH-mediated) and stoichiometric (consumption exceeding production in active disease). ^[9]

Therapeutic targeting of LEKTI – the emerging pipeline

The mechanistic clarity of the LEKTI/KLK5 axis has made it one of the most actively pursued therapeutic targets in barrier disease research. Three approaches have generated meaningful recent data:

LEKTI-grafted synthetic inhibitors. A November 2025 PMC study (PMC12670400) described a sunflower trypsin inhibitor (SFTI) scaffold grafted with LEKTI-derived residues from the D8–D11 region – the domain carrying the highest-affinity KLK5 binding loop. The lead compound (lead 7) achieved an IC50 of 14 ± 4 nM and Ki of 11 nM against KLK5, with high selectivity over other KLK family members. In keratinocytes from an NS patient – cells with no endogenous LEKTI whatsoever – lead 7 reduced KLK5 activity in a dose-dependent manner and improved epithelial barrier integrity as measured by transepithelial electrical resistance. Lead 7 also suppressed KLK5-mediated PAR2 activation – the signalling pathway through which KLK5 directly activates neurogenic inflammation and mast cell responses. ^[7]

The significance of the SFTI scaffold approach is translational: SFTI-based peptides are protease-resistant (the circular backbone of the sunflower inhibitor resists the degrading enzymes that rapidly clear most linear peptides at the skin surface), small enough for topical penetration, and cheap enough to synthesise at scale. Lead 7 is not in clinical trials yet, but the NS keratinocyte functional data represents the first direct evidence that a synthetic LEKTI-mimetic can restore barrier function in cells where the natural inhibitor is genetically absent. ^[7]

Dual KLK5/KLK7 antibody inhibition. A December 2022 Science Translational Medicine study (Inhibin, Regeneron) reported that dual inhibitory antibodies targeting KLK5 and KLK7 simultaneously produced meaningful barrier restoration and reduced inflammatory parameters in NS mouse models, with translational proteomic validation in NS patient skin biopsies. The dual-targeting rationale reflects what the LEKTI domain-specificity data confirms: D8–D11 inhibits both KLK5 and KLK7 (though with 10-fold less potency for KLK7), and full corneodesmosomal protection requires inhibiting the chymotrypsin-like substrate specificity of KLK7 in addition to the trypsin-like KLK5. A KLK5-only approach leaves the desmocollin-1 cleavage pathway running. ^[2]

Azelaic acid – the available clinical option. Azelaic acid suppresses KLK5 at the mRNA and protein expression level – not at the level of LEKTI/KLK5 complex formation, but upstream by reducing the amount of KLK5 available for LEKTI to regulate. In conditions where LEKTI’s regulatory capacity is being exceeded by excess KLK5 production (rosacea) or being stoichiometrically consumed (active NS), reducing KLK5 expression complements LEKTI function by reducing the substrate burden. This is the mechanistic basis for azelaic acid’s effectiveness in rosacea that the KLK5 entity establishes – and it connects to the LEKTI regulatory system as a supportive rather than replacement strategy. ^[9]